000178941 001__ 178941
000178941 005__ 20240229143600.0
000178941 0247_ $$2doi$$a10.1111/bpa.12970
000178941 0247_ $$2pmid$$apmid:35213082
000178941 0247_ $$2ISSN$$a1015-6305
000178941 0247_ $$2ISSN$$a1750-3639
000178941 0247_ $$2altmetric$$aaltmetric:123678164
000178941 037__ $$aDKFZ-2022-00357
000178941 041__ $$aEnglish
000178941 082__ $$a610
000178941 1001_ $$aBerghoff, Anna S$$b0
000178941 245__ $$aPrognostic impact of genetic alterations and methylation classes in meningioma.
000178941 260__ $$aOxford$$bWiley-Blackwell$$c2022
000178941 3367_ $$2DRIVER$$aarticle
000178941 3367_ $$2DataCite$$aOutput Types/Journal article
000178941 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1685705300_5389$$xReview Article
000178941 3367_ $$2BibTeX$$aARTICLE
000178941 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178941 3367_ $$00$$2EndNote$$aJournal Article
000178941 500__ $$a#LA:B300#
000178941 520__ $$aMeningiomas are classified based on histological features, but genetic and epigenetic features are emerging as relevant biomarkers for outcome prediction and may supplement histomorphological evaluation. We investigated meningioma-relevant mutations and their correlation with DNA methylation clusters and patient survival times. Formalin-fixed and paraffin-embedded samples of 126 meningioma patients (WHO grade I 52/126; 41.3%; WHO grade II: 48/126; 38.1%; WHO grade III: 26/126; 20.6%) were investigated. We analyzed NF2, TRAF7, KLF4, ARID, SMO, AKT, TERT promotor, PIK3CA, and SUFU mutations using panel sequencing and correlated them to DNA methylation classes (MC) determined using 850k EPIC arrays. The TRAKL mutation genotype was characterized by the presence of any of the following mutations: TRAF7, AKT1, and KLF4. Survival data including progression-free survival (PFS) and overall survival (OS) was retrieved from chart review. Mutations were evident in 90/126 (71.4%) specimens with mutations in NF2 (39/126; 31.0%), TRAF7 (39/126; 31.0%) and KLF4 (25/126; 19.8%) being the most frequent ones. Two or more mutations were observed in 35/126 (27.8%) specimens. While TRAKL was predominantly found in benign MC, NF2 was associated with malign MC (p < 0.05). TRAF7, KLF4, and TRAKL mutation genotype were associated with improved PFS and OS (p < 0.05). TERT promotor methylation, intermediate, and malign MC were associated with impaired PFS and OS (p < 0.05). Methylation cluster showed better prognostic discrimination for PFS and OS (c-index 0.77/0.75) than each of the individual mutations (c-index 0.63/0.68). In multivariate analysis correcting for age, gender, MC, and WHO grade, none of the individual mutations except TERT remained an independent significant prognostic factor for PFS. Molecular profiling including mutational analysis and DNA methylation classification may facilitate more precise prognostic assessment and identification of potential targets for personalized therapy in meningioma patients.
000178941 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000178941 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178941 650_7 $$2Other$$ameningioma
000178941 650_7 $$2Other$$amethylation classes
000178941 650_7 $$2Other$$amutation
000178941 650_7 $$2Other$$aprognosis
000178941 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1
000178941 7001_ $$aRicken, Gerda$$b2
000178941 7001_ $$aFurtner, Julia$$b3
000178941 7001_ $$0P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aSchrimpf, Daniel$$b4
000178941 7001_ $$aWidhalm, Georg$$b5
000178941 7001_ $$aRajky, Ursula$$b6
000178941 7001_ $$aMarosi, Christine$$b7
000178941 7001_ $$aHainfellner, Johannes A$$b8
000178941 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b9
000178941 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b10$$eLast author
000178941 7001_ $$00000-0003-3541-2315$$aPreusser, Matthias$$b11
000178941 773__ $$0PERI:(DE-600)2029927-8$$a10.1111/bpa.12970$$gVol. 32, no. 2$$n2$$pe12970$$tBrain pathology$$v32$$x1015-6305$$y2022
000178941 909CO $$ooai:inrepo02.dkfz.de:178941$$pVDB
000178941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000178941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000178941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000178941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000178941 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000178941 9141_ $$y2022
000178941 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2021-02-02$$wger
000178941 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000178941 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-02
000178941 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000178941 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000178941 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-09-26T13:10:13Z
000178941 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-09-26T13:10:13Z
000178941 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2022-09-26T13:10:13Z
000178941 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000178941 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000178941 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-17
000178941 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-17
000178941 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN PATHOL : 2021$$d2022-11-17
000178941 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000178941 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-17
000178941 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-17
000178941 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRAIN PATHOL : 2021$$d2022-11-17
000178941 9202_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000178941 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000178941 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x1
000178941 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000178941 980__ $$ajournal
000178941 980__ $$aVDB
000178941 980__ $$aI:(DE-He78)C060-20160331
000178941 980__ $$aI:(DE-He78)B300-20160331
000178941 980__ $$aI:(DE-He78)HD01-20160331
000178941 980__ $$aUNRESTRICTED